- Home
- CMA vs CORT Comparison
CMA vs CORT Comparison
Compare CMA & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMA | CORT |
|---|---|---|
| Founded | 1849 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 8.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CMA | CORT |
|---|---|---|
| Price | $88.96 | $82.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 6 |
| Target Price | $71.45 | ★ $130.20 |
| AVG Volume (30 Days) | ★ 1.4M | 999.2K |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 30.50 | N/A |
| EPS | ★ 5.23 | 0.87 |
| Revenue | ★ $3,234,000,000.00 | $741,172,000.00 |
| Revenue This Year | $6.32 | $23.96 |
| Revenue Next Year | $2.86 | $43.40 |
| P/E Ratio | ★ $17.01 | $94.62 |
| Revenue Growth | 2.31 | ★ 17.92 |
| 52 Week Low | $48.12 | $49.00 |
| 52 Week High | $90.44 | $117.33 |
Technical Indicators
Market Signals| Indicator | CMA | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 52.30 |
| Support Level | $88.34 | $80.38 |
| Resistance Level | $89.38 | $85.34 |
| Average True Range (ATR) | 1.54 | 3.46 |
| MACD | -0.07 | -0.44 |
| Stochastic Oscillator | 79.89 | 44.83 |
Price Performance
Historical ComparisonAbout CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.